AMG 732 for healthy volunteers and people with Thyroid Eye Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study has a Phase 1 (Part A) single-dose, randomized, placebo-controlled arm in healthy adults to measure safety and tolerability after single subcutaneous injections. Phase 2 (Part B) is a randomized, placebo-controlled multiple-dose arm in participants with Thyroid Eye Disease to see if AMG 732 improves clinical signs and symptoms. Both parts include safety monitoring with labs, vital signs, ECGs, and eye assessments. Phase 1 recruitment is closed and Phase 2 will open at selected U.S. sites.

Why it matters

Who can join: the full rules

Inclusion criteria for Part A/Phase 1 only:

* Participant has provided informed consent before initiation of any study-specific activities/procedures.
* Male or female aged 18 to 55 years (Part A).
* Female participants must be of non-childbearing potential.
* Body mass index (BMI) between 18 and 30 kg/m\^2, inclusive, at screening.
* The participant has adequate venous access and can receive intravenous (IV) therapy.
* The participant is considered by the investigator or designee to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead electrocardiogram (ECG) results, and physical examination findings at screening.
* Healthy Japanese participants in cohort 4 only. Japanese participants must meet all the following as confirmed by interview: Descendants of 4 ethnic Japanese grandparents who were born in Japan; Both parents are ethnic Japanese who were born in Japan; Hold a Japanese passport or identity papers; Have lived outside Japan for less than 10 years at the time of screening and lifestyle including diet has not changed significantly since leaving Japan.

Inclusion criteria for Part B/Phase 2 only:

* Male or female aged 18 to 65 years.
* Moderate-to-severe active TED.
* The participant had onset of active TED within 15 months prior to baseline.
* Clinical diagnosis of Graves' disease associated with active TED with a Clinical Activity Score (CAS)≥3 for the most severely affected eye at screening and baseline.
* Proptosis ≥18mm in the study eye at baseline.
* Participants with baseline subjective binocular diplopia score \>0.
* Does not require immediate surgical ophthalmological intervention and is not planning corrective surgery/irradiation during the trial.

Exclusion criteria for Part A and Part B:

* Malignant condition in the past 12 months or major surgery within 8 weeks or plans to have an elective surgery from screening through end of study.
* Active liver or kidney disfunction at screening.
* Positive test for hepatitis B/C or Human immunodeficiency virus (HIV) serology at screening.
* Glycated hemoglobin (HbA1c) \> 6.5% and/or fasting glucose levels\> 126 mg/dL (\> 7 mmol/L) at screening.
* Use of any steroid (IV, oral, steroid eye drops) within 3 weeks prior to the first dose. Steroids cannot be initiated during the trial. Exceptions include topical and inhaled steroids and steroids used to treat injection related reactions or short course of steroid for asthma control.
* Known hypersensitivity to teprotumumab or any other monoclonal antibody products.
* History of substance abuse within 12 months before screening.
* Donated blood, or had significant blood loss, or received a transfusion of any blood or blood products within 60 days prior to day 1 dosing or received a plasma donation within 7 days prior to day 1 dosing.

Exclusion criteria for PartA/Phase 1 only

• Blood pressure or ECG abnormalities at screening.

Exclusion criteria for Part B/Phase 2 only:

* Use of any steroid or other non-steroid immunosuppressive agent, monoclonal antibody, within 3 months prior to the first injection of study drug.
* Use of teprotumumab or any other IGF-1R inhibitor.
* Prior orbital irradiation or decompression in the study eye.
* History or existing inflammatory bowel disease (ulcerative colitis or Crohn's disease).

Other protocol-defined inclusion/exclusion criteria apply.

Where it's running

• Applied Research Center of Arkansas
  Little Rock, Arkansas, United States Recruiting
• Levenson Eye Associates
  Jacksonville, Florida, United States Recruiting
• Ilumina Medical Research
  Kissimmee, Florida, United States Recruiting
• Sarasota Retina Institute
  Sarasota, Florida, United States Recruiting
• Vision Medical Research, Inc.
  Orland Park, Illinois, United States Recruiting
• Ppd Las Vegas Research Unit
  Las Vegas, Nevada, United States Recruiting

Study contacts

• Study coordinator: Amgen Call Center
• Email: medinfo@amgen.com
• Phone: 866-572-6436

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imaging Comparison of 68Ga-FAPI and 68Ga-DOTATATE in Thyroid Eye Disease

  This study tests two PET imaging methods (FAPI and DOTATATE) to see which best images activity in the eyes of adults with thyroid eye disease.

  Recruiting Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT07835607

• IBI3031 in Thyroid Eye Disease (TED)

  A first-in-human test in adults with moderate-to-severe TED to see if IBI3031 is safe and tolerable when given by shot under the skin or into a vein.

  Recruiting Phase 1 Innovent Biologics (Suzhou) Co. Ltd. · Shenyang, Liaoning · NCT07622368

• AMG 732 for thyroid eye disease in a rollover, open-label study

  This study tests AMG 732 in adults with moderate-to-severe thyroid eye disease who previously did not respond or relapsed, to see if the treatment helps symptoms and is safe over a rollover period.

  Recruiting at 8 sites Phase 2 Amgen · Little Rock, Arkansas and 7 other locations · NCT07438405

• Teprotumumab N01 for adults with thyroid eye disease

  This will try Teprotumumab N01 in adults with recent-onset thyroid eye disease to see if it reduces eye inflammation and improves vision and quality of life.

  Recruiting Peking University Third Hospital · Beijing · NCT07423013

• Teprotumumab N01 vs IV steroids for active thyroid eye disease

  This trial tests whether teprotumumab N01 can help people with active thyroid eye disease better than intravenous steroids.

  Recruiting Phase 4 Innovent Biologics (Suzhou) Co. Ltd. · Shanghai, Shanghai Municipality · NCT07265258

• Testing IBI311 for inactive thyroid eye disease.

  This trial will test whether IBI311 improves eye signs and symptoms and is safe for people with inactive thyroid eye disease.

  Recruiting Phase 3 Innovent Biologics (Suzhou) Co. Ltd. · Shenyang, Liaoning · NCT07113262

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.